CHMP-EMA Issues Positive Opinion on Teclistamab for Relapsed/Refractory Myeloma, Adopts Changes to Marketing Authorization (https://www.myeloma.org/news-events/multiple-myeloma-news/chmp-positive-opinion-teclistamab-rrmm)